Arrhythmias (Atrial Fibrillation), Valvular Heart Disease & PAD
Key Takeaways
- In non-valvular atrial fibrillation, stroke risk is calculated using the CHA2DS2-VASc score; a score >=2 in men or >=3 in women warrants anticoagulation with a Direct Oral Anticoagulant (DOAC) preferred over Warfarin.
- Warfarin (target INR 2.0-3.0 or 2.5-3.5) remains mandatory over DOACs for anticoagulation in patients with mechanical heart valves or moderate-to-severe mitral stenosis.
- Aortic stenosis presents with the classic triad of exertional dyspnea, syncope, and angina, accompanied by a crescendo-decrescendo systolic ejection murmur at the right upper sternal border radiating to the carotid arteries.
- Ankle-Brachial Index (ABI) values <=0.90 confirm Peripheral Artery Disease (PAD), while values >1.40 indicate non-compressible, calcified vessels requiring a Toe-Brachial Index (TBI) evaluation.
- Cilostazol improves walking distance in patients with PAD claudication but is strictly contraindicated in patients with heart failure of any severity due to increased mortality.
Arrhythmias (Atrial Fibrillation), Valvular Heart Disease & PAD
Atrial Fibrillation: Pathophysiology, Classification, and ECG Diagnostics
Atrial Fibrillation (AFib) is the most common sustained cardiac arrhythmia. Disorganized atrial electrical activity originates predominantly from ectopic foci near the pulmonary veins in the left atrium. Rapid, uncoordinated atrial depolarizations (300-600 bpm) cause loss of the "atrial kick" (20-30% of end-diastolic filling), reducing cardiac output and causing blood stasis in the left atrial appendage, predisposing to thrombus formation and ischemic stroke.
AFib Classification:
- Paroxysmal AFib: Terminates spontaneously or with intervention within 7 days.
- Persistent AFib: Sustained >7 days, requiring cardioversion.
- Long-Standing Persistent AFib: Continuous AFib lasting >12 months under active rhythm control.
- Permanent AFib: Decision made to cease rhythm control attempts.
12-Lead ECG Triad:
- Absolutely irregularly irregular ventricular rhythm (variable R-R intervals).
- Complete absence of distinct P waves, replaced by chaotic baseline fibrillatory waves (f waves).
- Variable ventricular response (heart rate 110-180 bpm in untreated cases).
Atrial Fibrillation Management: Rate vs. Rhythm Control
Rate Control Strategy: Initial approach for most older adults (AFFIRM trial demonstrated equal mortality between rate and rhythm control).
- Target Heart Rate: Lenient rate control (resting HR <110 bpm) is acceptable for asymptomatic patients. Strict rate control (resting HR <80 bpm) is indicated for symptomatic patients or LV dysfunction.
- First-Line Pharmacotherapy: Beta-blockers (metoprolol, atenolol, carvedilol) or Non-dihydropyridine CCBs (diltiazem, verapamil). CONTRAINDICATION: Avoid diltiazem and verapamil in HFrEF (LVEF <=40%) due to negative inotropic effects. Digoxin is a second-line option in sedentary older adults.
Rhythm Control Strategy: Indicated for symptomatic or young patients using antiarrhythmics (amiodarone, flecainide, sotalol) or catheter ablation. Cardioversion Protocol: If AFib duration is >=48 hours (or unknown), the patient must be effectively anticoagulated for at least 3 weeks prior and 4 weeks post-cardioversion, OR undergo Transesophageal Echocardiography (TEE) to exclude left atrial appendage thrombus prior to cardioversion.
Thromboembolic Risk Stratification: CHA2DS2-VASc and Anticoagulation Rules
Stroke risk in non-valvular AFib is evaluated using the CHA2DS2-VASc score:
| CHA2DS2-VASc Risk Factor | Point Value |
|---|---|
| C - Congestive Heart Failure (or LVEF <=40%) | 1 point |
| H - Hypertension | 1 point |
| A2 - Age >=75 years | 2 points |
| D - Diabetes Mellitus | 1 point |
| S2 - Stroke / TIA / Thromboembolism history | 2 points |
| V - Vascular Disease (prior MI, PAD, aortic plaque) | 1 point |
| A - Age 65 to 74 years | 1 point |
| Sc - Sex Category: Female | 1 point |
Anticoagulation Recommendations:
- Score 0 in Men / 1 in Women: Low risk; no anticoagulation needed.
- Score 1 in Men / 2 in Women: Intermediate risk; oral anticoagulation considered.
- Score >=2 in Men / >=3 in Women: High risk; oral anticoagulation recommended (Class I).
DOACs vs. Warfarin Rules: Direct Oral Anticoagulants (Apixaban 5 mg BID, Rivaroxaban 20 mg daily, Dabigatran 150 mg BID) are preferred over Warfarin for non-valvular AFib due to lower intracranial bleeding risk and no INR monitoring. MANDATORY WARFARIN EXCEPTION: DOACs are STRICTLY CONTRAINDICATED in AFib with moderate-to-severe Mitral Stenosis OR mechanical heart valves. These patients MUST receive Warfarin (target INR 2.0-3.0 for mechanical aortic valve/mitral stenosis; target INR 2.5-3.5 for mechanical mitral valve).
Valvular Heart Disease: Aortic Stenosis, Regurgitation, Mitral Lesions
| Valvular Lesion | Classic Etiology & Symptoms | Physical Exam Murmur Characteristics | Management Rules |
|---|---|---|---|
| Aortic Stenosis (AS) | Senile calcification or bicuspid valve. Classic Triad: Angina, Syncope, Exertional Dyspnea (SAD). | Harsh crescendo-decrescendo systolic ejection murmur at RUSB radiating to carotid arteries. Delayed/weak carotid pulse (pulsus parvus et tardus), soft S2. | TTE gold standard (valve area <1.0 cm² = severe). TAVR or SAVR. Avoid aggressive vasodilators and diuretics. |
| Aortic Regurgitation (AR) | Aortic root dilation, endocarditis. | High-pitched blowing diastolic decrescendo murmur at LSB. Wide pulse pressure, Water-hammer pulse. | Afterload reduction (ACEi, nifedipine). Surgical replacement if symptomatic or EF <50%. |
| Mitral Regurgitation (MR) | Mitral valve prolapse, post-MI papillary muscle ischemia. | Holosystolic murmur at Apex radiating to left axilla. Associated S3 gallop. | Afterload reduction (ACEi/ARB). MitraClip or surgical repair. |
| Mitral Stenosis (MS) | Rheumatic heart disease history. | Opening snap followed by low-pitched diastolic rumbling murmur at Apex. | Anticoagulate with Warfarin (DOACs contraindicated). High AFib risk. |
Peripheral Artery Disease (PAD): Pathophysiology and Diagnostics
PAD is caused by lower extremity arterial atherosclerosis (superficial femoral, popliteal, iliac arteries). Risk factors include smoking (strongest), diabetes, hypertension, hyperlipidemia, and age.
- Intermittent Claudication: Exertional cramping calf/thigh pain relieved by 5-10 minutes of rest.
- Critical Limb Ischemia: Advanced disease with ischemic rest pain (distal foot pain worse at night in bed, relieved by dangling leg), non-healing punched-out arterial ulcers, or gangrene.
- Physical Exam: Diminished/absent DP and PT pulses, cool skin, hair loss, delayed capillary refill (>3 sec), elevation pallor, and dependent rubor (Buerger test).
Ankle-Brachial Index (ABI): Initial diagnostic test of choice (ankle SBP / brachial SBP):
- ABI >1.40: Non-compressible calcified vessels (common in diabetes/CKD). Requires Toe-Brachial Index (TBI <=0.70 confirms PAD).
- ABI 1.00-1.40: Normal.
- ABI 0.41-0.90: Mild-to-moderate PAD (claudication).
- ABI <=0.40: Severe PAD (critical limb ischemia).
Evidence-Based Management of PAD
- Risk Modification: Smoking cessation (single most effective intervention), High-intensity statin (Atorvastatin 80 mg), BP <130/80 mmHg, HbA1c <7%.
- Antiplatelet Therapy: Aspirin 81 mg daily OR Clopidogrel 75 mg daily.
- Exercise Therapy: Supervised Exercise Therapy (SET) 30-45 min 3x/week for 12+ weeks increases pain-free walking distance.
- Claudication Pharmacotherapy: Cilostazol 100 mg BID (PDE-3 inhibitor) improves walking distance. BLACK BOX WARNING CONTRAINDICATION: Cilostazol is STRICTLY CONTRAINDICATED in patients with HEART FAILURE of any severity due to increased mortality.
- Revascularization: Angioplasty/stenting or bypass graft indicated for critical limb ischemia or severe refractory claudication.
A 76-year-old male with a history of hypertension, type 2 diabetes, and a prior ischemic stroke is newly diagnosed with non-valvular atrial fibrillation. What is his CHA2DS2-VASc score, and what is the recommended anticoagulation strategy?
In which of the following clinical scenarios is a Direct Oral Anticoagulant (DOAC) strictly CONTRAINDICATED, making Warfarin with INR monitoring mandatory for stroke prevention?
An 81-year-old male presents with exertional syncope and angina. Physical exam reveals a harsh crescendo-decrescendo systolic ejection murmur at the right upper sternal border that radiates to the carotid arteries, accompanied by a delayed and weak carotid pulse upstroke. Which valvular lesion is most likely?
A 67-year-old patient with symptomatic peripheral artery disease (PAD) and severe calf claudication is being considered for medical therapy to increase pain-free walking distance. His medical history is notable for HFrEF (LVEF 35%). Which claudication medication is STRICTLY CONTRAINDICATED in this patient?